Literature DB >> 15479435

Aluminium compounds for use in vaccines.

Erik B Lindblad1.   

Abstract

Aluminium adjuvants are the most widely used adjuvants in both human and veterinary vaccines. These adjuvants have been used in practical vaccination for more than 60 years and are generally recognized as safe and as stimulators of Th2 immunity. The present review gives a short introduction to the pioneering research at the start of the use of aluminium compounds as adjuvants, including references on the chemistry of these compounds. Analytical methods for identifying the most commonly used aluminium compounds, such as boehmite and aluminium hydroxyphosphate, are mentioned. Emphasis is placed on the important factors for antigen adsorption and on the latest work using gene-deficient mice in the research of the mechanism of aluminium adjuvants in terms of cytokine and T-cell subset stimulation. Key references on the ability of aluminium adjuvants to stimulate IgE and also in vivo clearing of aluminium adjuvants are discussed. Furthermore, the review addresses the issue of local reactions in the context of injection route and local tissue disturbance. Possible new applications of aluminium adjuvants in, for example, combined aluminium-adsorbed protein and DNA oligonucleotide vaccines as well as the possible use of aluminium adjuvants in combination with IL-12 to stimulate Th1-type immune responses are mentioned. Copyright 2004 Australasian Society for Immunology Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479435     DOI: 10.1111/j.0818-9641.2004.01286.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  143 in total

1.  Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Authors:  I Tamayo; J M Irache; C Mansilla; J Ochoa-Repáraz; J J Lasarte; C Gamazo
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  Synergistic effect of aluminum and ionizing radiation upon ultrastructure, oxidative stress and apoptotic alterations in Paneth cells of rat intestine.

Authors:  N A Eltahawy; S M Elsonbaty; S Abunour; W E Zahran
Journal:  Environ Sci Pollut Res Int       Date:  2017-01-12       Impact factor: 4.223

3.  Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells.

Authors:  Denis Leclerc; Diane Beauseigle; Jérome Denis; Hélène Morin; Christine Paré; Alain Lamarre; Réjean Lapointe
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Construction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.

Authors:  Christopher G Earnhart; Richard T Marconi
Journal:  Vaccine       Date:  2007-01-17       Impact factor: 3.641

5.  Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes.

Authors:  Lea Barfod; Morten A Nielsen; Louise Turner; Madeleine Dahlbäck; Anja T R Jensen; Lars Hviid; Thor G Theander; Ali Salanti
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Invariant NKT cells sustain specific B cell responses and memory.

Authors:  Grazia Galli; Paola Pittoni; Elena Tonti; Carmine Malzone; Yasushi Uematsu; Marco Tortoli; Domenico Maione; Gianfranco Volpini; Oretta Finco; Sandra Nuti; Simona Tavarini; Paolo Dellabona; Rino Rappuoli; Giulia Casorati; Sergio Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

7.  Safety and efficiency of active immunization with detoxified antigen against scorpion venom: side effect evaluation.

Authors:  Nassrine Bachsais; Lila Boussag-Abib; Fatima Laraba-Djebari
Journal:  Inflamm Res       Date:  2017-05-17       Impact factor: 4.575

Review 8.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

Review 10.  Influenza vaccines.

Authors:  A H Ellebedy; R J Webby
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.